KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Work In Process (2018 - 2025)

Twist Bioscience (TWST) has disclosed Work In Process for 8 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Work In Process fell 12.02% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, down 12.02% year-over-year, with the annual reading at $2.3 million for FY2025, 5.55% up from the prior year.
  • Work In Process for Q4 2025 was $2.3 million at Twist Bioscience, up from $2.3 million in the prior quarter.
  • The five-year high for Work In Process was $4.8 million in Q3 2021, with the low at $611000.0 in Q2 2023.
  • Average Work In Process over 5 years is $2.5 million, with a median of $2.5 million recorded in 2021.
  • The sharpest move saw Work In Process tumbled 84.25% in 2023, then soared 262.19% in 2024.
  • Over 5 years, Work In Process stood at $3.1 million in 2021, then rose by 14.86% to $3.6 million in 2022, then crashed by 33.8% to $2.4 million in 2023, then increased by 10.33% to $2.6 million in 2024, then dropped by 12.02% to $2.3 million in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $2.3 million, $2.3 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.